20:36 , May 31, 2019 |  BC Extra  |  Financial News

New IPO filings include Adaptive, Morphic

Immunosequencing company Adaptive and integrin company Morphic each filed for IPOs on NASDAQ Thursday, while antipsychotic therapy developer Karuna revealed details of its planned listing on the exchange on Friday. Adaptive Biotechnologies Corp. (Seattle, Wash.)...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
18:46 , Feb 15, 2019 |  BC Week In Review  |  Financial News

TCR2 raises $75M in IPO

TCR2 Therapeutics Inc. (NASDAQ:TCRR) raised $75 million in an IPO priced Feb. 13. The immuno-oncology company priced 5 million shares at $15, the midpoint of its proposed range of $14-$16. The price valued TCR2 at...
05:01 , Feb 15, 2019 |  BC Extra  |  Financial News

Stealth Bio prices $78M IPO at bottom end of range

Stealth BioTherapeutics Corp. (NASDAQ:MITO) closed down $0.10 to $11.90 Friday after raising $78 million in its IPO. Late Thursday, the company priced more ADSs than anticipated at the bottom end of its proposed range. The...
05:02 , Feb 14, 2019 |  BC Extra  |  Financial News

TCR2 prices $75M IPO at midpoint

TCR2 Therapeutics Inc. (NASDAQ:TCRR) raised $75 million in an IPO priced late Wednesday. The company added $0.07 to $15.07 in its first day of trading Thursday. The immuno-oncology company priced 5 million shares at $15,...
00:28 , Jan 25, 2019 |  BC Week In Review  |  Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

In a bid to keep its IPO from getting bogged down by the U.S. government shutdown, Gossamer Bio Inc. (San Diego, Calif.) plans to take advantage of a rule allowing a company to file to...
00:33 , Jan 24, 2019 |  BC Extra  |  Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

In a bid to keep its IPO from getting bogged down by the U.S. government shutdown, Gossamer Bio Inc. (San Diego, Calif.) plans to take advantage of a rule allowing a company to file to...
23:18 , Jan 18, 2019 |  BioCentury  |  Finance

Broken window

A combination of bad calendar luck and the U.S. government shutdown is trending toward this being one of the slowest Januarys for biotech public financings in recent years. But a few deals are getting done...
05:21 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

Stealth BioTherapeutics Corp. (Newton, Mass.) proposed an IPO on NASDAQ late on Dec. 28, less than six months after filing to list on the Hong Kong stock exchange. The prospectus filed with the SEC on...
04:19 , Jan 4, 2019 |  BC Week In Review  |  Financial News

TCR2 seeks IPO as first program slated to enter clinic

Looking to bring at least one of its cell therapy programs to the clinic in 2019, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Dec. 28 to raise $100 million in an IPO on NASDAQ. TCR2...